286 related articles for article (PubMed ID: 34684085)
21. Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Macaluso FS; Giuliano A; Fries W; Viola A; Abbruzzese A; Cappello M; Giuffrida E; Carrozza L; Privitera AC; Magnano A; Ferracane C; Scalisi G; Minissale MG; Giangreco E; Garufi S; Bertolami C; Cucinotta U; Graziano F; Casà A; Renna S; Teresi G; Rizzuto G; Mannino M; Maida M; Orlando A
Inflamm Bowel Dis; 2023 Feb; 29(2):217-221. PubMed ID: 35385102
[TBL] [Abstract][Full Text] [Related]
22. Serological response to vaccination against coronavirus disease-19 in patients with inflammatory bowel disease.
Mathur A; Sahu S; Rai S; Ghoshal U; Ghoshal UC
Indian J Gastroenterol; 2023 Feb; 42(1):64-69. PubMed ID: 36598745
[TBL] [Abstract][Full Text] [Related]
23. COVID-19 in IBD: The experience of a single tertiary IBD center.
Rizzello F; Calabrese C; Salice M; Calandrini L; Privitera H; Melotti L; Peruzzi G; Dussias N; Belluzzi A; Scaioli E; Decorato A; Siniscalchi A; Filippone E; Laureti S; Rottoli M; Poggioli G; Gionchetti P
Dig Liver Dis; 2021 Mar; 53(3):271-276. PubMed ID: 33451910
[TBL] [Abstract][Full Text] [Related]
24. Disability and quality of life before and during the COVID-19 outbreak: A cross-sectional study in inflammatory bowel disease patients.
Azzam NA; Aljebreen A; Almuhareb A; Almadi MA
Saudi J Gastroenterol; 2020; 26(5):256-262. PubMed ID: 32415045
[TBL] [Abstract][Full Text] [Related]
25. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
[TBL] [Abstract][Full Text] [Related]
26. Seroprevalence study of SARS-CoV-2 antibodies in healthcare workers following the first wave of the COVID-19 pandemic in a tertiary-level hospital in the south of Ireland.
Faller E; Wyse A; Barry R; Conlon K; Everard C; Finnegan P; Foran C; Herlihy E; Kerr G; Lapthorne S; McGreal-Bellone A; Morrissey E; O'Sullivan D; O'Sullivan G; Eustace JA; Spillane D; Dempsey C; Benson J; Prentice M; Gallagher J; MacSharry J; Fanning LJ; O'Riordan S; Horgan M; Sadlier C
BMJ Open; 2021 Jun; 11(6):e051415. PubMed ID: 34103324
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System.
Khan N; Mahmud N; Trivedi C; Reinisch W; Lewis JD
Gut; 2021 Sep; 70(9):1657-1664. PubMed ID: 33753416
[TBL] [Abstract][Full Text] [Related]
28. Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence.
Esposito S; Caminiti C; Giordano R; Argentiero A; Ramundo G; Principi N
Front Immunol; 2022; 13():933774. PubMed ID: 35812420
[TBL] [Abstract][Full Text] [Related]
29. Seroprevalence of anti-SARS-CoV-2 antibodies in the Northern Italy population before the COVID-19 second wave.
Berselli N; Filippini T; Paduano S; Malavolti M; Modenese A; Gobba F; Borella P; Marchesi I; Vivoli R; Perlini P; Bellucci R; Bargellini A; Vinceti M
Int J Occup Med Environ Health; 2022 Feb; 35(1):63-74. PubMed ID: 34524275
[TBL] [Abstract][Full Text] [Related]
30. SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.
Fuereder T; Berghoff AS; Heller G; Haslacher H; Perkmann T; Strassl R; Berger JM; Puhr HC; Kreminger J; Moik F; Schubert L; Starzer AM; Steindl A; Winkler S; Preusser M; Tobudic S
ESMO Open; 2020 Sep; 5(5):e000889. PubMed ID: 32878898
[TBL] [Abstract][Full Text] [Related]
31. Cytokine signature in convalescent SARS-CoV-2 patients with inflammatory bowel disease receiving vedolizumab.
Dallari S; Martinez Pazos V; Munoz Eusse J; Wellens J; Thompson C; Colombel JF; Satsangi J; Cadwell K; Wong SY;
Sci Rep; 2024 Jan; 14(1):186. PubMed ID: 38168138
[TBL] [Abstract][Full Text] [Related]
32. Epidemiology of SARS-CoV-2 Infection Evaluated by Immunochromatographic Rapid Testing for the Determination of IgM and IgG Against SARS-CoV-2 in a Cohort of Mask Wearing Workers in the Metal-Mechanical Sector in an Area With a High Incidence of COVID-19.
Esposito S; Neglia C; Affanni P; Colucci ME; Argentiero A; Veronesi L; Messina G; Deolmi M; Principi N;
Front Public Health; 2021; 9():628098. PubMed ID: 34249830
[No Abstract] [Full Text] [Related]
33. Seroprevalence of SARS-CoV-2 IgG specific antibodies among healthcare workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave.
Barallat J; Fernández-Rivas G; Quirant-Sánchez B; González V; Doladé M; Martinez-Caceres E; Piña M; Matllo J; Estrada O; Blanco I
PLoS One; 2020; 15(12):e0244348. PubMed ID: 33370363
[TBL] [Abstract][Full Text] [Related]
34. Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of São Paulo, Brazil.
Tess BH; Granato CFH; Alves MCGP; Pintão MCT; Nunes MC; Rizzatti EG; Reinach FC
Braz J Infect Dis; 2021; 25(4):101604. PubMed ID: 34416142
[TBL] [Abstract][Full Text] [Related]
35. High Seroprevalence of SARS-CoV-2 among Healthcare Workers in a North Italy Hospital.
Airoldi C; Patrucco F; Milano F; Alessi D; Sarro A; Rossi MA; Cena T; Borrè S; Faggiano F
Int J Environ Res Public Health; 2021 Mar; 18(7):. PubMed ID: 33804893
[TBL] [Abstract][Full Text] [Related]
36. Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain.
Varona JF; Madurga R; Peñalver F; Abarca E; Almirall C; Cruz M; Ramos E; Castellano Vázquez JM
Int J Epidemiol; 2021 May; 50(2):400-409. PubMed ID: 33434269
[TBL] [Abstract][Full Text] [Related]
37. Safety of biologics in inflammatory bowel disease patients with COVID-19.
Weissman S; Aziz M; Smith WL; Elias S; Swaminath A; Feuerstein JD
Int J Colorectal Dis; 2021 Sep; 36(9):2051-2055. PubMed ID: 34131784
[TBL] [Abstract][Full Text] [Related]
38. PREVALENCE AND PREDICTIVE FACTORS ASSOCIATED WITH POSITIVITY OF SARS-COV-2 SEROLOGICAL MARKERS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AT AN IBD REFERRAL CENTER.
Ferreira SDC; Parra RS; Feitosa MR; Feres O; Santana RC; Troncon LEA
Arq Gastroenterol; 2022; 59(2):170-176. PubMed ID: 35830024
[TBL] [Abstract][Full Text] [Related]
39. Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic.
McGregor CG; Adams A; Sadler R; Arancibia-Cárcamo CV; Palmer R; Ambrose T; Brain O; Walsh A; Klenerman P; Travis SP; Croft NM; Lindsay JO; Satsangi J
Gut; 2021 Dec; 70(12):2398-2400. PubMed ID: 33579788
[No Abstract] [Full Text] [Related]
40. Seroprevalence of SARS-CoV-2 in healthcare workers from outpatient facilities and retirement or nursing homes in a Swiss canton.
Zürcher K; Mugglin C; Suter-Riniker F; Keller PM; Egger M; Müller S; Fluri M; Hoffmann M; Fenner L
Swiss Med Wkly; 2021 Aug; 151():w30021. PubMed ID: 34495604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
